Karthik Chintharala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Karthik Chintharala has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Abdallah AlSaafeen
EUMD, General Medicine Tbilisi State Medical University Tbilisi Georgia
1 shared publication - Aliya Shaju Shahul Hameed
East European University Tbilisi Georgia
1 shared publication - Amritaa Thalla
Internal Medicine Department, Maheshwara Medical College and Hospital, Patancheru, Telangana 502307, India, India
1 shared publication - Ana Carolina Putini Vieira
University of Santo Amaro, Department of Medicine, São Paulo, Brazil
1 shared publication - Ana Carolina Ventura de Santana de Jesus
Bahiana School of Medicine and Public Health, Department of Medicine, Salvador, Brazil
1 shared publication - Ana Leticia Fornari Caprara
Neurology Department, Cooper Norcross Health, Camden, NJ 08103, USA, USA
1 shared publication
Latest Publications
- Open Access
- 28 August 2026
- Published by MDPI AG in Preprints.org
Effects of Modafinil on Motor and Non-Motor Outcomes in Parkinson’s Disease: A Meta-Analysis and Systematic Review of Randomized, Placebo-Controlled Trials
Background: Excessive daytime sleepiness (EDS) and fatigue are prevalent non-motor symptoms of Parkinson’s disease (PD). Modafinil has been proposed as a management strategy. Evidence across individual trials remains inconsistent. This study aimed to evaluate the efficacy and safety of modafinil compared to placebo on motor and non-motor outcomes in PD. Methods: A systematic search of PubMed/Medline, Embase, and Cochrane Library databases was conducted for trials evaluating modafinil in PD up to March 2026. Inverse-variance methods with fixed-effect or random-effects models were used to determine weighted mean differences (MD) or standardized mean differences (SMD). The statistical heterogeneity was assessed using the I² statistic. Risk of bias was assessed using the Cochrane RoB 2 tool. PROSPERO (CRD420261420008). Results: Seven trials (N = 216; modafinil n = 113, placebo n = 103) met predefined eligibility criteria. Modafinil was associated with a significant reduction in EDS as measured by the Epworth Sleepiness Scale compared to placebo (MD −2.12; 95% CI −3.64 to −0.60; I2 = 65%). No significant effects were observed for fatigue (MD −0.17; 95% CI −1.12 to 0.79), depressive symptoms (SMD 1.51; 95% CI −0.10 to 3.11), or motor function (SMD 0.20; 95% CI −0.23 to 0.63). Adverse events, including insomnia, headache, dizziness, and gastrointestinal symptoms, were comparable between treatment and placebo groups. Conclusion: Modafinil may provide a modest but statistically significant improvement in EDS in PD without worsening motor function or increasing adverse events. No benefit could be elicited for fatigue or depressive symptoms. Larger, longer-duration trials with standardized outcome measures are warranted.
- 28 August 2026
- Published by MDPI AG in Preprints.org
Open AccessEffects of Modafinil on Motor and Non-Motor Outcomes in Parkinson’s Disease: A Meta-Analysis and Systematic Review of Randomized, Placebo-Controlled Trials
Background: Excessive daytime sleepiness (EDS) and fatigue are prevalent non-motor symptoms of Parkinson’s disease (PD). Modafinil has been proposed as a management strategy. Evidence across individual trials remains inconsistent. This study aimed to evaluate the efficacy and safety of modafinil compared to placebo on motor and non-motor outcomes in PD. Methods: A systematic search of PubMed/Medline, Embase, and Cochrane Library databases was conducted for trials evaluating modafinil in PD up to March 2026. Inverse-variance methods with fixed-effect or random-effects models were used to determine weighted mean differences (MD) or standardized mean differences (SMD). The statistical heterogeneity was assessed using the I² statistic. Risk of bias was assessed using the Cochrane RoB 2 tool. PROSPERO (CRD420261420008). Results: Seven trials (N = 216; modafinil n = 113, placebo n = 103) met predefined eligibility criteria. Modafinil was associated with a significant reduction in EDS as measured by the Epworth Sleepiness Scale compared to placebo (MD −2.12; 95% CI −3.64 to −0.60; I2 = 65%). No significant effects were observed for fatigue (MD −0.17; 95% CI −1.12 to 0.79), depressive symptoms (SMD 1.51; 95% CI −0.10 to 3.11), or motor function (SMD 0.20; 95% CI −0.23 to 0.63). Adverse events, including insomnia, headache, dizziness, and gastrointestinal symptoms, were comparable between treatment and placebo groups. Conclusion: Modafinil may provide a modest but statistically significant improvement in EDS in PD without worsening motor function or increasing adverse events. No benefit could be elicited for fatigue or depressive symptoms. Larger, longer-duration trials with standardized outcome measures are warranted.
- Open Access
- 11 October 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (10) , e70984
Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers
Introduction: Narcolepsy Type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness (EDS), cataplexy, and REM intrusions, caused by a deficiency of orexin (hypocretin), a hypothalamic neuropeptide essential for arousal, REM sleep regulation, metabolism, and emotional stability. This review synthesizes and critically analyzes the pathophysiological, clinical, and therapeutic dimensions of orexin deficiency in narcolepsy, with particular emphasis on recent advances from 2023 to 2025. Methods: This narrative analytical review analyzed 50 peer‐reviewed publications covering the neurobiology of the orexin system, diagnostic evolution of NT1, comparative symptomatology of central hypersomnia disorders, and recent therapeutic innovations. Out of which 16 studies were selected based on relevance, recency, and translational impact. Results: Recent research confirms that over 90% of NT1 patients exhibit cerebrospinal fluid (CSF) orexin‐A levels below 110 pg/mL and carry the HLA‐DQB1*06:02 allele, indicating a strong genetic and immunological association. Postmortem analyses have revealed a loss of up to 95% of orexin‐producing neurons in the lateral hypothalamus. In a 2024 multicenter trial, danavorexton (a selective orexin receptor‐2 [OX2R] agonist) was associated with a mean improvement of 11.1 points on the Maintenance of Wakefulness Test, outperforming modafinil and suggesting the feasibility of receptor‐level restoration. In addition, intermediate orexin levels (110–200 pg/mL) have been documented in a subset of patients with narcolepsy Type 2 (NT2) and idiopathic hypersomnia (IH), challenging the binary diagnostic threshold and prompting reevaluation of orexin's diagnostic role. Orexin dysfunction has also been correlated with high psychiatric comorbidity rates, including major depressive disorder in 40% and anxiety disorders in nearly 30% of NT1 patients. These manifestations reflect orexin's broader role in regulating REM sleep, metabolic processes, and autonomic stability. Conclusion: Orexin deficiency remains the central mechanism underlying NT1, with far‐reaching implications in psychiatric and neurodegenerative disease. While emerging orexin‐targeted therapies offer promising disease‐modifying potential, critical challenges persist in standardizing biomarkers, resolving NT2 classification ambiguities, and ensuring global access to therapeutics.
- 11 October 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (10) , e70984
Open AccessOrexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers
Introduction: Narcolepsy Type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness (EDS), cataplexy, and REM intrusions, caused by a deficiency of orexin (hypocretin), a hypothalamic neuropeptide essential for arousal, REM sleep regulation, metabolism, and emotional stability. This review synthesizes and critically analyzes the pathophysiological, clinical, and therapeutic dimensions of orexin deficiency in narcolepsy, with particular emphasis on recent advances from 2023 to 2025. Methods: This narrative analytical review analyzed 50 peer‐reviewed publications covering the neurobiology of the orexin system, diagnostic evolution of NT1, comparative symptomatology of central hypersomnia disorders, and recent therapeutic innovations. Out of which 16 studies were selected based on relevance, recency, and translational impact. Results: Recent research confirms that over 90% of NT1 patients exhibit cerebrospinal fluid (CSF) orexin‐A levels below 110 pg/mL and carry the HLA‐DQB1*06:02 allele, indicating a strong genetic and immunological association. Postmortem analyses have revealed a loss of up to 95% of orexin‐producing neurons in the lateral hypothalamus. In a 2024 multicenter trial, danavorexton (a selective orexin receptor‐2 [OX2R] agonist) was associated with a mean improvement of 11.1 points on the Maintenance of Wakefulness Test, outperforming modafinil and suggesting the feasibility of receptor‐level restoration. In addition, intermediate orexin levels (110–200 pg/mL) have been documented in a subset of patients with narcolepsy Type 2 (NT2) and idiopathic hypersomnia (IH), challenging the binary diagnostic threshold and prompting reevaluation of orexin's diagnostic role. Orexin dysfunction has also been correlated with high psychiatric comorbidity rates, including major depressive disorder in 40% and anxiety disorders in nearly 30% of NT1 patients. These manifestations reflect orexin's broader role in regulating REM sleep, metabolic processes, and autonomic stability. Conclusion: Orexin deficiency remains the central mechanism underlying NT1, with far‐reaching implications in psychiatric and neurodegenerative disease. While emerging orexin‐targeted therapies offer promising disease‐modifying potential, critical challenges persist in standardizing biomarkers, resolving NT2 classification ambiguities, and ensuring global access to therapeutics.
- 15 February 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (3) , 1033-1042
Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials
Mirikizumab, an interleukin-23 (IL-23) p19 subunit inhibitor, has emerged as a promising treatment for moderate-to-severe plaque psoriasis. Despite its promising results, a comprehensive synthesis of clinical data is essential to assess its overall efficacy and safety profile. We searched PubMed, Embase, and Cochrane for studies assessing mirikizumab in moderate-to-severe psoriasis. A random-effects model using Inverse Variance (IV) computed mean differences (MD) for continuous outcomes and risk ratios (RR) for binary endpoints. Risk Difference (RD) studies were analysed using generic inverse variance (GIV) in Review Manager. Statistical analyses were conducted using R software version 4.2.1, following PRISMA guidelines. This analysis of three RCTs involving 1,649 adult patients over 16-52 weeks demonstrated mirikizumab's significant efficacy in treating psoriasis. At 16 weeks, mirikizumab substantially reduced Body Surface Area (BSA) to < 1% (RR: 34.53, p < 0.001) and improved PASI scores (PASI 100 RR: 25.94, PASI 90 RR: 11.50, PASI 75 RR: 10.47, all p < 0.001). Static Physician's Global Assessment (sPGA) scores of 0/1 were achieved (RR: 12.48, p < 0.001). Quality of life measures also improved significantly, with increases in SF-36 Physical and Mental Component Summaries (MD: 4.02 and 3.53 respectively, p < 0.01) and Dermatology Life Quality Index (DLQI) scores of 0/1 (RD: 0.51, p < 0.00001). Importantly, the safety profile of mirikizumab was comparable to the control, with no significant differences in the overall incidence of adverse effects (RR: 0.97; 95% CI: 0.86-1.10) or in serious adverse effects (RR: 1.61; 95% CI: 0.55-4.73). These results collectively demonstrate the efficacy and safety of mirikizumab in treating psoriasis, with significant improvements across multiple clinical and quality-of-life measures. This meta-analysis demonstrates that mirikizumab significantly reduces psoriasis severity and improves quality of life, with a favourable safety profile. These findings support its use as a valuable treatment option for moderate-to-severe plaque psoriasis. Further research is needed to assess long-term outcomes and comparative effectiveness.
- 15 February 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (3) , 1033-1042
Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials
Mirikizumab, an interleukin-23 (IL-23) p19 subunit inhibitor, has emerged as a promising treatment for moderate-to-severe plaque psoriasis. Despite its promising results, a comprehensive synthesis of clinical data is essential to assess its overall efficacy and safety profile. We searched PubMed, Embase, and Cochrane for studies assessing mirikizumab in moderate-to-severe psoriasis. A random-effects model using Inverse Variance (IV) computed mean differences (MD) for continuous outcomes and risk ratios (RR) for binary endpoints. Risk Difference (RD) studies were analysed using generic inverse variance (GIV) in Review Manager. Statistical analyses were conducted using R software version 4.2.1, following PRISMA guidelines. This analysis of three RCTs involving 1,649 adult patients over 16-52 weeks demonstrated mirikizumab's significant efficacy in treating psoriasis. At 16 weeks, mirikizumab substantially reduced Body Surface Area (BSA) to < 1% (RR: 34.53, p < 0.001) and improved PASI scores (PASI 100 RR: 25.94, PASI 90 RR: 11.50, PASI 75 RR: 10.47, all p < 0.001). Static Physician's Global Assessment (sPGA) scores of 0/1 were achieved (RR: 12.48, p < 0.001). Quality of life measures also improved significantly, with increases in SF-36 Physical and Mental Component Summaries (MD: 4.02 and 3.53 respectively, p < 0.01) and Dermatology Life Quality Index (DLQI) scores of 0/1 (RD: 0.51, p < 0.00001). Importantly, the safety profile of mirikizumab was comparable to the control, with no significant differences in the overall incidence of adverse effects (RR: 0.97; 95% CI: 0.86-1.10) or in serious adverse effects (RR: 1.61; 95% CI: 0.55-4.73). These results collectively demonstrate the efficacy and safety of mirikizumab in treating psoriasis, with significant improvements across multiple clinical and quality-of-life measures. This meta-analysis demonstrates that mirikizumab significantly reduces psoriasis severity and improves quality of life, with a favourable safety profile. These findings support its use as a valuable treatment option for moderate-to-severe plaque psoriasis. Further research is needed to assess long-term outcomes and comparative effectiveness.